Acute Myeloid Leukemia (AML) Treatment Market Analysis APAC - Size and Forecast 2024-2028

APAC Acute Myeloid Leukemia Treatment Market Size 2024-2028

The APAC acute myeloid leukemia (AML) treatment market size is forecast to increase by USD 305.8 million at a CAGR of 13.9% between 2023 and 2028. The market is witnessing significant growth due to the high incidence of this cancer type worldwide. According to the American Cancer Society, AML accounts for approximately one-third of all leukemia diagnoses. A key trend in the market is the adoption of Chimeric Antigen Receptor T-cell (CAR-T) therapy for AML treatment. This innovative approach, which involves engineering a patient's own T-cells to target and destroy cancer cells, has shown promising results in clinical trials. However, challenges remain, particularly in developing nations, where the lack of adequate healthcare infrastructure hampers the widespread adoption of advanced treatment modalities. Despite these challenges, the market is expected to grow steadily due to the increasing demand for effective AML treatments and ongoing research and development efforts.

What will be the Size of the Market During the Forecast Period?

Request Free Sample

Acute Myeloid Leukemia (AML), a type of bone marrow cancer characterized by the production of abnormal myeloid cells, is a significant health concern worldwide. Genetic mutations, unhealthy lifestyles, hazardous chemicals, and radiation exposure are known risk factors for this disease. In APAC, the number of AML cases is growing due to population aging and rising awareness about the disease. AML treatment in APAC involves various approaches such as chemotherapy, targeted therapies, and novel therapies. Chemotherapy, which includes induction chemotherapy administered through parenteral or oral routes, is the most common treatment for high-risk AML patients.

Moreover, this therapy aims to destroy the abnormal myeloblasts and stimulate the production of healthy white blood cells. The immune system plays a crucial role in the body's defense against leukemia. However, in some cases, the immune system may not be able to effectively target the abnormal myeloid cells. In such situations, targeted therapies, which use drugs or other substances to specifically target cancer cells, can be effective. Novel therapies, such as gene therapy and stem cell transplantation, are also being explored for the treatment of AML. AML treatment in APAC is provided in hospitals and clinics, including specialized centers. The immune system plays a crucial role in the treatment of AML, with ongoing research focusing on harnessing its potential through cancer immunotherapies. The market for AML treatment is expected to witness significant growth due to the increasing incidence of AML, advancements in technology, and the development of new therapies.

In addition, screening programs are being implemented to increase early detection and improve patient outcomes. The diagnosis of AML involves various tests, including bone marrow aspiration and cytogenetic analysis to identify chromosomal abnormalities. AML can be further classified into two types: myeloblastic leukemia and lymphoblastic leukemia. Myeloblastic leukemia, also known as acute myeloid leukemia with myelodysplasia-related changes, is a subtype of AML characterized by the presence of myelodysplastic syndrome (MDS) features. This subtype is more common in older adults and has a poorer prognosis than other types of AML. In conclusion, the AML treatment market in APAC is witnessing significant growth due to the increasing number of cases and the availability of advanced therapeutic options.

Moreover, chemotherapy, targeted therapies, and novel therapies are the main treatment approaches used in the region. The role of hospitals and clinics, including specialized centers, in providing AML treatment is crucial. Early detection through screening programs and advancements in treatment technologies are key trends driving the growth of the AML treatment market in APAC.

Market Segmentation

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

• Type
  • Chemotherapy
  • Stem cell transplantation
  • Others
• Geography
  • APAC
    • China
    • India
    • Japan

By Type Insights

The chemotherapy segment is estimated to witness significant growth during the forecast period.Acute Myeloid Leukemia (AML) is a type of cancer affecting the blood and bone marrow, requiring effective treatment approaches. Chemotherapy is a common treatment method for AML, utilizing drugs such as cytarabine, anthracycline, fludarabine, mitoxantrone, etoposide (VP-16), 6-thioguanine (6-TG), hydroxyurea, corticosteroid drugs, methotrexate (MTX), 6-mercaptopurine (6-MP), azacytidine, decitabine, daunomycin, idarubicin, and mitoxantrone. The chemotherapy segment is expected to experience substantial growth during the forecast period due to the presence of leading pharmaceutical companies like Novartis AG, Pfizer Inc., Teva Pharmaceuticals, and AbbVie Inc., offering advanced chemotherapy drugs for AML treatment. Chemotherapy plays a crucial role in eliminating cancer cells that have spread throughout the body, contributing significantly to managing AML.

Furthermore, immunotherapy and homecare are emerging treatment modalities for AML, while health technology assessment, precision medicine, and clinical trials are essential for ensuring effective and safe treatments. Home healthcare and health technology assessment are increasingly being utilized to improve patient outcomes. Precision medicine, an approach that tailors treatment to individual genetic makeup, is gaining traction in the field of AML. Oral medications and parenteral routes are the primary administration methods for these therapies.

Get a glance at the market share of various segments Request Free Sample

The chemotherapy segment accounted for USD 123.60 million in 2018 and showed a gradual increase during the forecast period.

Our market researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

APAC Acute Myeloid Leukemia (AML) Treatment Market Driver

High incidence of acute myeloid leukemia is the key driver of the market. The incidence of Acute Myeloid Leukemia (AML) in the Asia-Pacific (APAC) region is on the rise, leading to a growing demand for effective treatment options. For instance, in Australia alone, approximately 5,202 new leukemia cases were reported in 2022, with a significant portion being AML. The aging population in APAC further increases the prevalence of this disease, as age is a known risk factor. Advancements in pharmacology and molecular biology are driving innovation in AML treatment, with targeted therapies and stem cell transplants gaining popularity. Chemotherapy remains the primary approach for both induction and consolidation phases, but targeted therapies, which focus on specific abnormalities in the myeloblastic leukemia cells, offer improved efficacy and reduced side effects.

Moreover, the market is segmented into various modalities, including chemotherapy, targeted therapies, and stem cell transplants. Induction chemotherapy is the standard treatment for AML, but parenteral administration of these drugs can be challenging and costly. Targeted therapies, which can be administered orally or through intravenous infusion, offer a more convenient and cost-effective alternative. Despite the high costs associated with stem cell transplantation, it remains a crucial option for eligible patients, particularly those with chromosomal abnormalities or refractory disease. Health reimbursement programs and screening programs are essential for increasing access to these treatments and improving patient outcomes. In conclusion, the rising incidence of AML in the APAC region, coupled with advancements in pharmacology and molecular biology, is driving growth and innovation in the AML treatment market. Targeted therapies and stem cell transplants offer promising alternatives to traditional chemotherapy, and health reimbursement and screening programs are essential for increasing access to these treatments.

APAC Acute Myeloid Leukemia (AML) Treatment Market Trends

CAR T-cell therapy for AML is the upcoming trend in the market. Acute Myeloid Leukemia (AML), a type of blood cancer, poses significant challenges in treatment due to various factors. Genetic mutations, unhealthy lifestyles, hazardous chemicals, and radiation exposure contribute to the development of high-risk AML cases. Traditional chemotherapy and bone marrow transplantation have limitations, leading to the exploration of advanced therapeutics. Quizartinib, a type of targeted therapy, has shown promise in treating AML by inhibiting FLT3 signaling. However, the emergence of resistance and limited efficacy in certain patient populations necessitates the development of novel therapies. One such approach is the use of Chimeric Antigen Receptor T-cell (CAR T-cell) therapy. Despite its success in treating B-cell leukemias and lymphomas, CAR T-cell therapy faces challenges in AML due to the difficulty of identifying specific antigens on AML cells without affecting healthy hematopoietic stem cells and the immunosuppressive tumor microenvironment.

In addition, recent innovations aim to overcome these obstacles by targeting multiple antigens, such as ADG2RE2 and CLEC12A, simultaneously to enhance specificity while minimizing damage to healthy cells. Additionally, combining CAR T-cell therapy with existing drugs like azacitidine has shown potential in increasing target antigen density on AML cells, thereby improving tumor-killing capabilities.

APAC Acute Myeloid Leukemia (AML) Treatment Market Challenge

Lack of adequate healthcare infrastructure in developing nations is a key challenge affecting the market growth. In the Asia Pacific region, the market for Acute Myeloid Leukemia (AML) treatment is primarily focused on hospitals and specialty centers for administration due to the large-scale infrastructure and advanced equipment required for radiotherapy and chemotherapy. However, the limited healthcare infrastructure in underdeveloped and emerging economies, such as India, China, Sri Lanka, and others, poses a significant challenge to the adoption of cancer treatment. With healthcare expenditure being a concern, only a select few healthcare institutions in these countries can afford and utilize advanced radiotherapy systems for AML treatment. The World Health Organization (WHO) recommends one teletherapy unit per million population.

Furthermore, based on this recommendation, India, for instance, would require approximately 1,250 teletherapy units against the presently available 545 units, indicating a substantial deficit of around 700 units. This shortfall significantly limits the number of radiotherapy and chemotherapy procedures, despite their high demand. However, the large-sized radiotherapy and chemotherapy devices require significant installation space, posing a challenge for underdeveloped and emerging economies with limited healthcare infrastructure and expenditure. In homecare settings and ambulatory care centers, oral administration of AML treatment drugs is gaining popularity due to their ease of use and convenience. However, the market for oral AML treatment drugs in the Asia Pacific region is still in its nascent stages and faces challenges related to regulatory approvals and reimbursement policies. The mortality and morbidity rates associated with AML are high, making it crucial to expand the availability of effective treatment options in the region.

Exclusive Customer Landscape

The market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.

Customer Landscape

Key Companies & Market Insights

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.

AbbVie Inc. - The company offers AML treatment for blood cancer patients.

The market research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:

• Agios Inc.
• Amgen Inc.
• Astellas Pharma Inc.
• Astex Pharmaceuticals Inc.
• Bristol Myers Squibb Co.
• CTI BioPharma Corp.
• Cyclacel Pharmaceuticals, Inc.
• Daiichi Sankyo Co. Ltd.
• F. Hoffmann La Roche Ltd.
• GlaxoSmithKline Plc
• Jazz Pharmaceuticals Plc
• Johnson and Johnson Services Inc.
• MEI Pharma Inc
• Novartis AG
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Research Analyst Overview

Acute Myeloid Leukemia (AML), a type of bone marrow cancer, is characterized by the production of abnormal myeloid cells that impede the normal function of white blood cells, immune system, and other essential elements in the body. Risk factors for AML include genetic mutations, unhealthy lifestyles, exposure to hazardous chemicals, and radiation. Current treatments for high-risk AML patients include chemotherapy, targeted therapies, and novel therapies. Chemotherapy, often administered via parenteral or oral medications, aims to destroy cancer cells. Immunotherapy, which harnesses the power of the immune system, is another promising approach. Quizartinib, a targeted therapy, is a promising treatment for AML patients with specific genetic mutations.

Moreover, precision medicine, which tailors treatment to individual patients based on their genetic makeup, is a burgeoning area of research in AML. Innovative therapies, such as stem cell transplantation and myeloblastic leukemia, offer hope for patients with advanced disease. Health technology assessment, clinical trials, and drug approvals are crucial components of the evolving AML treatment landscape. AML can affect various organs, including the liver, spleen, central nervous system, lymph nodes, and testicles. Early detection through screening programs is essential to improve outcomes. Sedentary lifestyles and poor health reimbursement policies pose challenges to effective AML management. Hospitals and clinics, specialty centers, homecare settings, and ambulatory care centers provide essential services for AML patients. Mortality and morbidity remain high, underscoring the need for continued research and development of advanced therapeutics.

Request Free Sample

What are the Key Data Covered in this Market Research Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the market growth and forecasting between 2024 and 2028
• Precise estimation of the size of the market and its contribution of the market in focus to the parent market
• Accurate predictions about upcoming market growth and trends and changes in consumer behaviour
• Growth of the market across APAC
• Thorough analysis of the market's competitive landscape and detailed information about companies
• Comprehensive analysis of factors that will challenge the growth of market companies

We can help! Our analysts can customize this market research report to meet your requirements Get in touch